Viropro, Inc. (VPRO)

[gapshot]

hey folks anyone read this today February 04, 2011 10:00 AM Eastern Time
Research and Markets: Competitor Analysis: G-CSF and GM-CSF 2011

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/44f15d/competitor_analysi) has announced the addition of the "Competitor Analysis: G-CSF and GM-CSF" report to their offering.

The present Competitive Intelligence Report about G-CSF & GM-CSF products in the pipeline and off-patent products provides a competitor evaluation in the field of G-CSF & GM-CSF branded products in regulated markets and products in non-regulated markets, biosimilars (biogenerics, follow-on biologics) and next generation, longer acting products or new uses of G-CSF as of January 2011. Purchase of the downloadable PDF report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently marketed branded and non-branded G-CSF and GM-CSF products in regulated and non-regulated markets for treatment of chemotherapy-induced neutropenia. The report includes the market size of branded G-CSF products in 2009. It lists the most advanced biosimilars of G-CSF and pegylated G-CSF and of GM-CSF. It describes the companies with G-CSF and GM-CSF products and of pegylated versions in non-regulated markets. In addition, the report lists company-specific R&D pipelines of G-CSF/GM-CSF products and projects. Competitor projects are listed in a tabular format providing Information on:

* Drug Codes,
* Target / Mechanism of Action,
* Class of Compound,
* Company,
* Territory,
* Indication,
* R&D Stage and
* additional comments with a hyperlink leading to the source of information.

Key Topics Covered:

* 1st Generation branded G-CSF products in regulated markets
* Biosimilar 1st generation G-CSF products in regulated markets
* Next generation G-CSF products and uses in regulated markets
* Biosimilar next generation G-CSF products and uses in regulated markets
* 1st generation G-CSF products in non-regulated markets
* Next generation G-CSF products in non-regulated markets
* 1st and next generation GM-CSF products in regulated markets
* 1st and next generation GM-CSF products in non-regulated markets
* About La Merie

48 Companies Mentioned, Some Include:

Corporate G-CSF & GM-CSF R&D Pipelines

* Acorn Biomedical
* Amgen
* Apricus Biosciences
* Beijing SL
* Pharmaceutical Co
* Bolder BioTechnology
* Cangene
* Dong-A Pharmaceutical
* Fuji Pharma
* Genzyme
* Green Cross
* Hospira
* Intas Biopharmaceuticals
* Kyowa Hakko Kirin Pharma
* NCPC GeneTech Biotechnology Development
* Octapharma
* Phage Pharmaceuticals
* PharmaEssentia
* Recoly
* Reliance GeneMedix
* Reliance Life Sciences
* Serum Institute of India
* Shandong GeneLeuk Biopharma
* USV Ltd.
* Xiamen Amoytop Biotech
* Zenotech Laboratories
* Zydus Cadila